Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TIMI (Thrombolytics and Myocardial Infarction Study) Troponin-I data guide interventionists:

This article was originally published in Clinica

Executive Summary

Heart attack patients with raised troponin-I should be treated more aggressively, according to data from the TIMI-IIIB trial (Thrombolytics and Myocardial Infarction Study). Patients with elevated levels had a significantly better outcome if they underwent early intervention rather than a conservative strategy of catheterisation followed by intervention, said Dr Elliot Antman of the Brigham & Women's Hospital during a presentation at the American Heart Association's annual meeting (Anaheim, California). For every ng/ml that troponin-I increased, mortality rose 10%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT094169

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel